The introduction of Retatrutide ZPHC, at a strength of 120mg, is sparking considerable excitement within the medical community. This groundbreaking dual GIP and GLP-1 agonist medication seems to deliver significant improvements in body loss compared to previous therapies. Initial research data have shown significant declines in body fat percentage,